Gilead Sciences had its Relative Strength (RS) Rating upgraded from 89 to 92 Tuesday.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's unique RS Rating tracks market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research reveals that the market's biggest winners typically have an RS Rating north of 80 in the early stages of their moves.
Gilead Sciences is trying to complete a consolidation with a 119.96 buy point. See if it can break out in volume at least 40% above average. Note that it's a third-stage base. Such later-stage patterns are more likely to fail than earlier-stage consolidations.
Gilead Sciences reported 0% EPS growth in its most recent report, while sales growth came in at 0%.
Gilead Sciences earns the No. 11 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
